On June 3, 2025, Plus Therapeutics, Inc. was notified by Nasdaq that it regained compliance with equity requirements after filing its quarterly report, though it previously reported a deficit of ($23.6 million) as of March 31, 2025. The company plans to appeal a possible delisting decision to a panel by June 10, 2025.